Drug Trial Radar · NCT06596772
A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
501
Actual
Start
Oct 3, 2024
Primary completion
Feb 20, 2026
Study completion Feb 20, 2026
Sponsor
- Lead sponsor
- mAbxience Research S.L.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 \[proposed etanercept biosimilar\] to Enbrel® \[EU-sourced\] in rheumatoid arthritis
Conditions
- Rheumatoid Arthritis (RA)
Interventions
MB04 (proposed biosimilar to etanercept)Drug
MB04 50 mg/week via subcutaneous injection
Enbrel (etanercept)Drug
Enbrel 50 mg/week via subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- American College of Rheumatology 20% Response Criteria (ACR20)Time frame: Week 24
Locations
60 sites in 6 countries. Site status is shown where the registry gives one.
Research site 2007
Haskovo, Bulgaria
Research site 2005
Plovdiv, Bulgaria
Research Site 2002
Rousse, Bulgaria
Research site 2001
Sofia, Bulgaria
Research Site 2003
Sofia, Bulgaria
Research Site 2008
Sofia, Bulgaria
Research site 2004
Vidin, Bulgaria
Research site 2006
Vratsa, Bulgaria
Research site 7004
Batumi, Georgia
Research site 7010
Batumi, Georgia
Research site 7001
Tbilisi, Georgia
Research site 7002
Tbilisi, Georgia
Research site 7003
Tbilisi, Georgia
Research site 7005
Tbilisi, Georgia
Research site 7006
Tbilisi, Georgia
Research site 7007
Tbilisi, Georgia
Research site 7009
Tbilisi, Georgia
Research Site 1301
Chisinau, Moldova
Research site 1302
Chisinau, Moldova
Research site 1303
Chisinau, Moldova
Research Site 1603
Bialystok, Poland
Research Site 1614
Bialystok, Poland
Research site 1616
Bialystok, Poland
Research site 1613
Bydgoszcz, Poland
Research site 1623
Bytom, Poland
Research Site 1615
Elblag, Poland
Research Site 1627
Elblag, Poland
Research Site 1606
Gdynia, Poland
Research Site 1611
Katowice, Poland
Research Site 1617
Krakow, Poland
Research Site 1622
Lublin, Poland
Research site 1605
Nowa Sól, Poland
Research Site 1618
Opole, Poland
Research site 1628
Piotrkow Trybunalski, Poland
Research Site 1624
Poniatowa, Poland
Research Site 1601
Poznan, Poland
Research Site 1602
Poznan, Poland
Research Site 1608
Poznan, Poland
Research Site 1619
Poznan, Poland
Research Site 1621
Poznan, Poland
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.